Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 25 July 2026
2022-11-15 10:30:00 Tuesday ET

Stock market misvaluation and corporate investment payout The behavioral catering theory suggests that stock market misvaluation can have a first-order
2017-11-07 09:38:00 Tuesday ET

HPE CEO Meg Whitman has run both eBay and Hewlett Packard within Fortune 500 and now has decided to step down after her 6-year stint at the technology giant
2025-10-04 13:37:00 Saturday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2018-12-11 10:34:06 Tuesday ET

Several eminent American China-specialists champion the key notion of *strategic engagement* with the Xi administration. From the Hoover Institution at Stan
2018-01-23 06:38:00 Tuesday ET

Amazon, Berkshire Hathaway, and JPMorgan Chase establish a new company to reduce U.S. employee health care costs in negotiations with drugmakers, doctors, a
2023-01-03 09:34:00 Tuesday ET

USPTO fintech patent protection and accreditation As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved